Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3

NCT00656006 is registered in ClinicalTrials.gov with Human Genome Sciences Inc. as lead sponsor.

NCT NCT00656006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00656006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3
Lead sponsor
Human Genome Sciences Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
April 30, 2007
Enrollment
43 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c